Skip to content
stoqly

Colgate-Palmolive

CL NYSE Household Products Financials FY2016–FY2025

Colgate-Palmolive's revenue rose 1.4% to $20.4 billion in fiscal 2025. Its operating margin was 16.2%, down from 21.2% a year earlier. Free cash flow was $3.6 billion, up 2.5%. It paid out $3.0 billion in dividends and buybacks, 83% of free cash flow. The diluted share count fell 1.5%.

Last close · Oct 23, 2026

$94.04

3.4%
Value it Compare
Revenue Total sales reported in the income statement.
$20.4B
1.4% vs prior year
Operating margin Operating income as a share of revenue.
16.2%
5.0 pts
Net income Profit after all expenses, interest and tax.
$2.1B
26.2%
Free cash flow Cash from operations minus capital spending.
$3.6B
2.5%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
37.3%
8.6 pts
Market cap Last close times the latest diluted share count, so it is approximate.
$75.4B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
37.2x
On $2.53 EPS (TTM)

What Colgate-Palmolive does

Colgate-Palmolive makes and sells everyday household and personal care products and pet food. Its products are marketed in over 200 countries and territories. It sells toothpaste, toothbrushes and mouthwash under names such as Colgate, elmex and Tom's of Maine, and soaps, shower gels and deodorants such as Palmolive, Softsoap and Speed Stick. It also sells dishwashing liquids, household cleaners and fabric conditioners such as Ajax, Fabuloso and Suavitel.

The company has two segments. Oral, Personal and Home Care brought in 44%, 17% and 16% of 2025 net sales. The Hill's Pet Nutrition segment, which sells Hill's Science Diet and Prescription Diet through pet stores, vets and online retailers, brought in 23%. Other customers include retailers, wholesalers and distributors. Walmart and its affiliates accounted for about 11% of net sales in 2025, and no other customer was as large.

Colgate-Palmolive had about 33,600 employees in over 100 countries at the end of 2025. About two-thirds of its revenue comes from outside the United States. It says it competes with multinational and local companies, with store-brand products, and with new online and direct-to-consumer sellers, on price, promotions, new products and expansion into new channels.

Legal name
COLGATE-PALMOLIVE COMPANY
Fiscal year ends
December 31, 2025
Latest annual report
10-K · Feb 23, 2026
Accession · CIK
0000021665-26-000006
0000021665

Revenue and margins

Colgate-Palmolive had $20.4B of revenue in fiscal 2025, up 1.4% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

From fiscal 2016 to 2025, diluted EPS grew −0.4% a year. Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was $3.6B in fiscal 2025, 17.8% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Colgate-Palmolive returned $3.0B to shareholders in fiscal 2025, 83% of free cash flow. The diluted share count fell 1.5%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Value Colgate-Palmolive yourself

Change the assumptions and see what they imply per share. These are models, not forecasts or price targets — the answer depends entirely on what you put in.

Discounted cash flow

Value per share

—

Adds net cash of −$6.4B and divides by 811.1M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.

Earnings multiple

Value per share

—

Reference multiples: today 37.2x · peers 17.8x · sector 24.2x.

Balance sheet

Cash, debt and the ratios that show how comfortably Colgate-Palmolive can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $832M$775M$1.1B$1.3B$1.4B
Debt incl. finance leases $7.2B$8.8B$8.2B$7.0B$7.8B
Net debt / EBITDA 1.6x2.3x1.6x1.2x1.6x
Interest coverage 27.8x17.3x13.9x14.6x12.4x
Current ratio 1.1x1.3x1.1x0.9x0.8x
Quick ratio 0.7x0.8x0.7x0.6x0.5x
Total assets $15.0B$15.7B$16.4B$16.0B$16.3B
Total liabilities $14.1B$14.9B$15.4B$15.5B$16.0B
Shareholders' equity $609M$401M$609M$212M$54.0M
Net debt (− = net cash) $6.4B$8.0B$7.1B$5.7B$6.4B

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$50.7M

7 insiders

Of sales under plans

0%

$0.0M

DateInsiderTradeSharesPriceValueFiling
Aug 24, 2026 Panagiotis TsourapasCOO, Cd, Emea, APac, Skin Sold 10,000 $92.05 $0.9M Form 4
Aug 6, 2026 John T CahillDirector Sold 4,170 $93.37 $0.4M Form 4
Aug 5, 2026 Noel R. WallaceChairman, President & CEO, Director Sold 161,021 $92.52 $14.9M Form 4
Aug 4, 2026 Noel R. WallaceChairman, President & CEO, Director Sold 161,021 $91.92 $14.8M Form 4
May 15, 2026 Gregory MalcolmEVP and Controller Sold 2,300 $88.44 $0.2M Form 4
May 7, 2026 Sally MasseyChief People Officer Sold 8,599 $87.41 $0.8M Form 4
Feb 12, 2026 Panagiotis TsourapasCOO, Eur., APac, Afr Eur, Skin Sold 15,000 $97.81 $1.5M Form 4
Feb 11, 2026 Panagiotis TsourapasCOO, Eur., APac, Afr Eur, Skin Sold 35,000 $94.61 $3.3M Form 4
Feb 10, 2026 John HazlinChief Growth Officer Sold 20,989 $94.25 $2.0M Form 4
Feb 6, 2026 Gregory MalcolmEVP and Controller Sold 12,747 $94.91 $1.2M Form 4
Feb 5, 2026 Sally MasseyChief Human Resources Officer Sold 15,851 $95.03 $1.5M Form 4
Feb 4, 2026 Stanley J Sutula IIIChief Financial Officer Sold 97,843 $94.27 $9.2M Form 4

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY23FY24FY25
Net income is positive ✓ ✓ ✓
Cash from operations is positive ✓ ✓ ✓
Return on assets rose ✓ ✓ ✕
Cash from operations exceeds net income ✓ ✓ ✓
Debt fell relative to assets ✓ ✓ ✕
Current ratio rose ✕ ✕ ✕
Share count didn't rise ✓ ✓ ✓
Gross margin rose ✓ ✓ ✕
Revenue rose relative to assets ✓ ✕ ✓
F-score 8 / 97 / 95 / 9
Accruals ratio −9.0%−7.5%−12.8%
Altman Z'' 6.946.966.23

Similar companies

Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.

CompanyMarket capGrowthOp. marginFCF marginROICP/EF-score
Colgate-Palmolive CL $75.4B 1.4% 16.2% 17.8% 37.3% 37.2x 5
Kimberly-Clark KMB $36.7B −2.1% 14.3% 10.0% 21.5% 18.7x 6 Compare →
Church & Dwight CHD $25.1B 1.6% 17.4% 17.6% 14.6% 33.7x 6 Compare →
Reynolds Consumer Products REYN $4.9B 0.7% — 8.5% 9.9% 14.7x 5 Compare →
Central Garden & Pet CENT $2.8B −2.2% 8.0% 9.3% 9.7% 16.8x 8 Compare →

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $15.2B $15.5B $15.5B $15.7B $16.5B $17.4B $18.0B $19.5B $20.1B $20.4B
Gross profit $9.1B $9.3B $9.2B $9.3B $10.0B $10.4B $10.2B $11.3B $12.2B $12.3B
Research and development $289M $285M $277M $281M $290M $307M $320M $343M $355M $366M
Operating income $4.0B $3.7B $3.7B $3.6B $3.9B $3.3B $2.9B $4.0B $4.3B $3.3B
Interest expense $155M $156M $195M $193M $184M $120M $167M $287M $292M $267M
Pretax income $3.7B $3.5B $3.5B $3.3B $3.6B $3.1B $2.7B $3.4B $4.0B $3.1B
Income tax $1.2B $1.3B $906M $774M $787M $749M $693M $937M $907M $798M
Net income $2.4B $2.0B $2.4B $2.4B $2.7B $2.2B $1.8B $2.3B $2.9B $2.1B
Diluted EPS $2.72 $2.28 $2.75 $2.75 $3.14 $2.55 $2.13 $2.77 $3.51 $2.63
Diluted shares 0.90B 0.89B 0.87B 0.86B 0.86B 0.85B 0.84B 0.83B 0.82B 0.81B
Cash flow
Cash from operations $3.1B $3.1B $3.1B $3.1B $3.7B $3.3B $2.6B $3.7B $4.1B $4.2B
Capital expenditure $593M $553M $436M $335M $409M $567M $696M $705M $561M $564M
Free cash flow $2.5B $2.5B $2.6B $2.8B $3.3B $2.8B $1.9B $3.0B $3.5B $3.6B
Depreciation and amortization $443M $475M $511M $519M $539M $556M $545M $567M $605M $630M
Stock-based compensation $123M $127M $109M $100M $107M $135M $125M $122M $135M $155M
Acquisitions $5.0M $0.0M $728M $1.7B $353M $0.0M $809M $0.0M $0.0M $293M
Share buybacks $1.3B $1.4B $1.2B $1.2B $1.5B $1.3B $1.3B $1.1B $1.7B $1.2B
Dividends paid $1.5B $1.5B $1.6B $1.6B $1.7B $1.7B $1.7B $1.7B $1.8B $1.8B
Dividends and buybacks $2.8B $2.9B $2.8B $2.8B $3.1B $3.0B $3.0B $2.9B $3.5B $3.0B
Balance sheet
Cash and short-term investments $1.3B $1.5B $726M $883M $888M $832M $775M $1.1B $1.3B $1.4B
Total debt $6.5B $6.6B $6.4B $7.6B $7.3B $7.2B $8.8B $8.2B $7.0B $7.8B
Finance lease liabilities $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Current assets $4.3B $4.6B $3.8B $4.2B $4.3B $4.4B $5.1B $5.3B $5.3B $5.7B
Current liabilities $3.3B $3.4B $3.3B $4.0B $4.4B $4.1B $4.0B $4.7B $5.8B $6.9B
Inventory $1.2B $1.2B $1.3B $1.4B $1.7B $1.7B $2.1B $1.9B $2.0B $2.0B
Property and equipment, net $3.8B $4.1B $3.9B $3.8B $3.7B $3.7B $4.3B $4.6B $4.4B $4.7B
Total assets $12.1B $12.7B $12.2B $15.0B $15.9B $15.0B $15.7B $16.4B $16.0B $16.3B
Total liabilities $12.1B $12.4B $12.0B $14.5B $14.8B $14.1B $14.9B $15.4B $15.5B $16.0B
Shareholders' equity −$243M −$60.0M −$102M $117M $743M $609M $401M $609M $212M $54.0M
Margins
Gross margin 60.0% 60.1% 59.4% 59.4% 60.8% 59.6% 57.0% 58.2% 60.5% 60.1%
Operating margin 26.0% 24.0% 23.8% 22.7% 23.6% 19.1% 16.1% 20.5% 21.2% 16.2%
EBITDA margin 28.9% 27.1% 27.1% 26.0% 26.9% 22.3% 19.1% 23.4% 24.2% 19.3%
Net margin 16.1% 13.1% 15.4% 15.1% 16.4% 12.4% 9.9% 11.8% 14.4% 10.5%
FCF margin 16.8% 16.2% 16.9% 17.8% 20.1% 15.8% 10.4% 15.6% 17.6% 17.8%
Returns
Return on capital 50.9% 44.0% 49.2% 41.6% 41.1% 33.9% 26.5% 34.3% 45.9% 37.3%
Return on capital employed 45.9% 41.0% 40.8% 35.9% 34.5% 29.6% 25.5% 34.1% 38.9% 33.5%
Return on assets 20.3% 16.3% 19.3% 17.4% 17.4% 14.0% 11.6% 14.3% 17.8% 13.2%
Growth
Revenue growth −5.2% 1.7% 0.6% 1.0% 5.0% 5.8% 3.1% 8.3% 3.3% 1.4%
Net income growth 76.4% −17.1% 18.6% −1.4% 13.9% −19.6% −17.6% 28.9% 25.6% −26.2%
EPS growth 79.0% −16.2% 20.6% 0.0% 14.2% −18.8% −16.5% 30.1% 26.7% −25.1%
FCF growth 12.8% −1.8% 4.8% 6.8% 18.3% −16.7% −32.6% 63.4% 16.6% 2.5%
Share count change −1.2% −1.2% −1.7% −1.4% −0.2% −1.3% −1.1% −1.1% −0.7% −1.5%
Financial health
Net debt / EBITDA 1.2x 1.2x 1.3x 1.7x 1.5x 1.6x 2.3x 1.6x 1.2x 1.6x
Interest coverage 25.5x 23.8x 18.9x 18.4x 21.1x 27.8x 17.3x 13.9x 14.6x 12.4x
Current ratio 1.3x 1.4x 1.1x 1.0x 1.0x 1.1x 1.3x 1.1x 0.9x 0.8x
Quick ratio 1.0x 1.0x 0.8x 0.7x 0.6x 0.7x 0.8x 0.7x 0.6x 0.5x
Capital allocation
Capex / revenue 3.9% 3.6% 2.8% 2.1% 2.5% 3.3% 3.9% 3.6% 2.8% 2.8%
Stock comp / revenue 0.8% 0.8% 0.7% 0.6% 0.7% 0.8% 0.7% 0.6% 0.7% 0.8%
Payouts / FCF 111.6% 117.1% 108.0% 100.6% 94.6% 108.7% 161.2% 94.6% 99.5% 83.5%
Quality scores
Piotroski F-score 8.0 8.0 6.0 7.0 6.0 6.0 6.0 8.0 7.0 5.0
Altman Z'' 8.1 7.9 8.1 6.6 6.5 7.0 6.9 6.9 7.0 6.2
Accruals ratio −5.8% −8.3% −5.3% −5.6% −6.6% −7.5% −5.0% −9.0% −7.5% −12.8%

Source: SEC EDGAR XBRL filings (CIK 0000021665). Data updated October 9, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open